In a patient with systemic lupus erythematosus presenting with unilateral lower‑extremity edema, what is the appropriate diagnostic work‑up and management?

Unilateral Lower Extremity Edema in Lupus: Diagnostic Work-Up and Management

In a lupus patient presenting with unilateral lower extremity edema, you must immediately rule out deep vein thrombosis (DVT) and antiphospholipid syndrome (APS)-related thrombosis with urgent Doppler ultrasound, followed by comprehensive evaluation for thrombotic microangiopathy (TMA), APS nephropathy, and lupus nephritis.

Immediate Diagnostic Priority: Rule Out Thrombosis

The unilateral presentation is a red flag for thrombotic complications, particularly given that approximately 30% of SLE patients have antiphospholipid antibodies 1. Your first step must be:

• Urgent lower extremity Doppler ultrasound to exclude DVT
• If positive, proceed immediately to anticoagulation evaluation

Comprehensive Laboratory Work-Up

Once thrombosis is excluded or identified, obtain the following tests simultaneously:

Thrombotic/Hematologic Panel

• Complete blood count with peripheral smear (looking for schistocytes suggesting TMA)
• Lactate dehydrogenase (LDH), haptoglobin, indirect bilirubin (hemolysis markers)
• ADAMTS13 activity and anti-ADAMTS13 antibodies (for TTP evaluation) 1
• Antiphospholipid antibody panel: lupus anticoagulant, anticardiolipin antibodies, anti-β2-glycoprotein I antibodies 1

Renal Assessment

• Urinalysis with microscopy
• Urine protein-to-creatinine ratio
• Serum creatinine and estimated GFR
• Complement levels (C3, C4, CH50)
• Anti-dsDNA antibodies 1

Additional Studies

• Serum albumin (to assess for nephrotic syndrome)
• Thyroid function tests (exclude hypothyroidism as cause of non-pitting edema)

Diagnostic Algorithm Based on Findings

If TMA is Present (thrombocytopenia + hemolysis + elevated creatinine):

Calculate PLASMIC score immediately 1. If intermediate-to-high risk for TTP in adults:

• Start plasma exchange and high-dose glucocorticoids immediately while awaiting ADAMTS13 results
• Do not delay treatment for confirmatory testing
• Add rituximab and/or caplacizumab once TTP is confirmed (ADAMTS13 activity ≤10%) 1

In children, TTP is less common and plasma exchange carries higher morbidity, so you can defer plasma exchange for 24-48 hours until ADAMTS13 results return 1.

If Antiphospholipid Antibodies are Positive:

Initiate long-term anticoagulation with warfarin (target INR 2-3) 1. This is critical because:

• In a retrospective study of 97 patients with kidney TMA, anticoagulated aPLA-positive patients showed 59.5% complete response versus 30.8% without anticoagulation 1
• Do not use direct oral anticoagulants—they are inferior to warfarin in preventing thromboembolic events in APS 1

If catastrophic APS is suspected (rapid-onset multi-organ thrombosis):

• High-dose glucocorticoids
• Plasma exchange (associated with improved survival) 1
• Consider rituximab or eculizumab 1

If Lupus Nephritis is Identified:

Proceed according to kidney biopsy findings and proteinuria level, with consideration of belimumab or voclosporin in addition to standard immunosuppression 2.

If Edema Appears to be SLE Flare-Related:

While bilateral non-pitting edema has been reported as a manifestation of SLE flare 3, 4, unilateral presentation is atypical. However, if other causes are excluded and SLEDAI score indicates active disease:

• Initiate or increase glucocorticoids (prednisone 0.5-1 mg/kg/day)
• Add diuretics for symptomatic relief
• Escalate immunosuppression as needed based on overall disease activity 2, 5

Critical Pitfalls to Avoid

1. Never assume unilateral edema is simply a lupus flare without excluding thrombosis—the unilateral nature demands vascular imaging
2. Do not use DOACs in APS—warfarin is the only acceptable anticoagulant 1
3. Do not delay plasma exchange in adults with suspected TTP—mortality is high without immediate treatment 1
4. Do not miss lupus nephritis—always check urinalysis and urine protein even if the primary complaint is peripheral edema 1

Co-Management Considerations

When TMA is identified, co-manage with an experienced hematologist when available 1. The complexity of distinguishing between TTP, APS-related TMA, and complement-mediated TMA requires specialized expertise, though treatment should not be delayed while arranging consultation.